Cabometyx Improves Survival Without Progression in Previousl

Patients with previously treated advanced neuroendocrine tumors who received treatment with Cabometyx had improved progression-free survival compared with placebo.

Related Keywords

Dana Farber Cancer Institute , Massachusetts , United States , Boston , Jennifera Chan , , Harvard Medical School , Neuroendocrine Tumors At Dana Farber Cancer Institute , National Cancer Institute , Gastrointestinal Cancer Center , Program In Carcinoid , National Cancer , Neuroendocrine Tumors , News , Tumors ,